Biofrontera AG

As of March 31, 2026, Biofrontera AG carries a market capitalization of 15.56M, placing it among publicly traded companies globally. Its enterprise value stands at 11.02M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Biofrontera AG's next confirmed earnings release is scheduled for November 19, 2026.

As of March 31, 2026, Biofrontera AG has 6.08M shares outstanding.

As of March 31, 2026, Biofrontera AG trades at a trailing price-to-earnings ratio of 6.02. The price-to-sales ratio is 1.37, and the price-to-book ratio stands at 0.91.

These figures are as of March 31, 2026. The EV/Sales ratio of 0.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 11.02M versus a market cap of 15.56M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Biofrontera AG maintains a current ratio of 2.96, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.79, indicating elevated leverage, while an interest coverage ratio of -147.69 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Biofrontera AG posted a return on equity (ROE) of 14.50, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 9.95, measuring how efficiently the asset base is converted into earnings. The company generates approximately 134,305.88 in revenue per employee across its workforce of 85.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.28 indicates how many times Biofrontera AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Biofrontera AG recorded 568,000.00 in income tax expense. The company reported a pretax loss of -2.87M and 2.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Biofrontera AG's stock has gained approximately 15.65% over the past 52 weeks. The 50-day moving average sits at 2.81, while the 200-day moving average is 2.58.

Over the twelve months ended March 31, 2026, Biofrontera AG generated 11.42M in revenue and converted that into 2.61M in net income, yielding earnings per share of -0.56. EBITDA reached -2.36M, while operating income came in at -2.36M.

As of March 31, 2026, Biofrontera AG holds 5.69M in cash and equivalents against 1.16M in total debt, resulting in a net debt position of -4.48M. Total book value stands at 17.10M, with working capital of 8.77M providing operational flexibility.

Over the twelve months ended March 31, 2026, Biofrontera AG posted a gross margin of 88.66, reflecting its pricing power and cost economics. The operating margin of -20.71 and net profit margin of 22.83 provide insight into operational efficiency.

Biofrontera AG's most recent stock split took place on May 14, 2024.

As of March 31, 2026, Biofrontera AG has an Altman Z-Score of -5.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.